title: Trastuzumab biosimilar shows potential for breast cancer.
authors.forename: Holly
authors.initials: H
authors.lastname: Baker
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage; D013810:Therapeutic Equivalency; D013997:Time Factors; D000068878:Trastuzumab / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000074322:Antineoplastic Agents, Immunological; D059451:Biosimilar Pharmaceuticals; D043823:Taxoids; D000068878:Trastuzumab